| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 02/27/2002 | CN1337956A New Morpholinobenzamide salts |
| 02/27/2002 | CN1337952A 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
| 02/27/2002 | CN1337949A Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid as TACE inhibitor |
| 02/27/2002 | CN1337947A Acetylenic sulfonamide thiol TACE inhibitors |
| 02/27/2002 | CN1337945A Alkynyl containing hydroxamic acid compounds as TACE inhibitors |
| 02/27/2002 | CN1337944A Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid as TACE inhibitors |
| 02/27/2002 | CN1337941A Amide derivatives |
| 02/27/2002 | CN1337931A Retinoid antagonists and use thereof |
| 02/27/2002 | CN1337268A Capillary artemisia for treating hepatocirrhosis and liver ascites |
| 02/27/2002 | CN1337267A Chinese medicine decoction for eliminating purplish and white patches on the skin |
| 02/27/2002 | CN1337263A Kidney invigorating and Yang strenthening medicine and its prepn |
| 02/27/2002 | CN1337244A Colera treating medicine |
| 02/27/2002 | CN1337238A Hepatitis treating medicine |
| 02/27/2002 | CN1337228A Application of lipoic acid for improving biological utilization ratio of mineral salt |
| 02/27/2002 | CN1337167A Healthy tea |
| 02/27/2002 | CN1079674C Flavanolignan preparation, its processing method and pharmaceutical compositions containing them |
| 02/26/2002 | US6350907 Matrix metalloprotease inhibitors |
| 02/26/2002 | US6350782 Use of basic amino acids derivatives for lowering ceramide levels |
| 02/26/2002 | US6350757 Cns disorders; serotonergic activity on receptors of the 5-ht.sub.2 family. |
| 02/26/2002 | US6350747 Protein serine/threonine kinase and protein tyrosine kinase enzyme inhibitors; angiogenesis inhibitors; antitumor and antiproliferative agents |
| 02/26/2002 | US6350744 Pyrmidine or pyridine derivatives; antiarthritic and antiinflammatory agents; cachexia treatment; interleukin and tumor necrosis factor inhibitors |
| 02/26/2002 | US6350735 Purine derivatives |
| 02/26/2002 | US6350446 Polypeptides with amino acid sequences for kidney failure |
| 02/26/2002 | US6350435 Composition for the treatment of halitosis |
| 02/26/2002 | CA2284470C New crystalline form of omeprazole |
| 02/26/2002 | CA2206776C N-sulfonylindoline derivatives carrying an amide functional group, their preparation and the pharmaceutical compositions in which they are present |
| 02/26/2002 | CA2170097C Thiophene compounds; process for preparing the same and pharmaceutical compositions containing them |
| 02/26/2002 | CA2160966C Piperidine derivatives; process for preparing them and compositions containing the same |
| 02/26/2002 | CA2024672C Indole, benzofuran,and benzothiophene containing lipoxygenase inhibiting compounds |
| 02/26/2002 | CA2012978C Treatment of hepatic diseases using fk 506 and related compounds |
| 02/26/2002 | CA2006717C Antibacterial anti-plaque oral composition mouthwash or liquid dentifrice |
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014499A2 Claudin polypeptides |
| 02/21/2002 | WO2002014485A2 Kallikrein gene |
| 02/21/2002 | WO2002014470A2 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth |
| 02/21/2002 | WO2002014370A1 Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof |
| 02/21/2002 | WO2002014369A2 Human kininogen d5 domain polypeptides and their use |
| 02/21/2002 | WO2002014356A2 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | WO2002014349A2 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/21/2002 | WO2002014319A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 02/21/2002 | WO2002014311A2 Urea compounds and methods of uses |
| 02/21/2002 | WO2002014310A1 2-[5-AMINO-6-OXO-2-PHENYL-1,6-DIHYDRO-1-PYRIMIDYL]-N-[1-(2-[5-t-BUTYL-1,3,4-OXADIAZOLYL]CARBONYL)-2-(R,S)-METHYLPROPYL]ACETAMIDE HYDROCHLORIDE |
| 02/21/2002 | WO2002014285A1 Substituted imidazoles as tafia inhibitors |
| 02/21/2002 | WO2002014282A1 2-aminopyridine compounds and use thereof as drugs |
| 02/21/2002 | WO2002014281A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | WO2002014276A1 Benzoylaminoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof |
| 02/21/2002 | WO2002014273A1 Indoline derivatives as 5ht2c antagonists |
| 02/21/2002 | WO2002014272A1 (thio)urea derivatives, process for their production and medicines containing the derivatives |
| 02/21/2002 | WO2002014271A1 Proline derivatives and use thereof as drugs |
| 02/21/2002 | WO2002014267A1 Novel aminocyclohexane derivatives |
| 02/21/2002 | WO2002014262A1 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |
| 02/21/2002 | WO2002013862A2 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | WO2002013861A2 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | WO2002013823A1 Micronized torsemide |
| 02/21/2002 | WO2002013821A1 Novel alicyclic imidazoles as h3 agents |
| 02/21/2002 | WO2002013775A1 Dental products comprising bone growth enhancing peptide |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001085256A3 Critical illness neuropathy |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001078533A3 Nutritional modules |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001076554A3 Drug delivery composition and device |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001066597A3 Inflammation-related gene |
| 02/21/2002 | WO2001066089A3 Pharmaceutical compositions comprising cannabis |
| 02/21/2002 | WO2001062901A3 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 02/21/2002 | WO2001058910A3 Lipid-based drug delivery systems |
| 02/21/2002 | WO2001054711A3 Use of neurotoxins for treating diabetes |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001042225A3 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 02/21/2002 | WO2001037812A3 Gastroretentive controlled release pharmaceutical dosage forms |
| 02/21/2002 | WO2001032871A3 Follistatin-related protein zfsta4 |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | US20020022816 Device |
| 02/21/2002 | US20020022729 Pyridylfuran and pyridylthiophene compounds |
| 02/21/2002 | US20020022667 For inducing or maintaining anesthesia or sedation in a patient |
| 02/21/2002 | US20020022648 Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists |
| 02/21/2002 | US20020022645 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor |
| 02/21/2002 | US20020022642 As nitric oxide synthase (NOS) inhibitors, used in therapy and prophylaxis of central nervous system disorders, inflammatory disorders, septic shock and other disorders |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022635 For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration |
| 02/21/2002 | US20020022628 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 02/21/2002 | US20020022620 Reverse-turn mimetics and methods relating thereto |
| 02/21/2002 | US20020022619 Administering to the mammal suffering from anxiety, depression and other disorders related to excessive corticotropin releasing factor an effective amount of tricyclic pyridine or pyrimidine derivatives |
| 02/21/2002 | US20020022615 Cyclic oxyguanidine protease inhibitors |
| 02/21/2002 | US20020022610 Compositions and methods for treating bacterial infections |
| 02/21/2002 | US20020022595 Treating inflammation resulting from a response of the non-specific defense system in a mammal by administering an antiinflammatory agent and the uncontaminated Mac-1 alpha subunit |
| 02/21/2002 | US20020022254 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | US20020022236 Accurately measuring albumin in urine sample; obtain urine, detect presence of adjusted and wildtype albumin in sample |
| 02/21/2002 | US20020022015 Administration system for seronegative of hepatitis C virus |
| 02/21/2002 | DE10038639A1 New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism |
| 02/21/2002 | CA2804958A1 Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | CA2419133A1 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth |
| 02/21/2002 | CA2419081A1 Micronized torsemide |
| 02/21/2002 | CA2419073A1 Novel alicyclic imidazoles as h3 agents |
| 02/21/2002 | CA2419008A1 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |